Clinical trials · Massachusetts
Alzheimer’s disease clinical trials in Massachusetts
We’re tracking 50 recruiting alzheimer’s disease studies with a site in Massachusetts — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT06416072Enrolling by invitation
Blood marker study for people not eligible for Alzheimer's prevention trials
This study looks at blood markers in people who were part of an early Alzheimer's prevention study but did not qualify for it because their amyloid levels were too low. It aims to understand brain changes and possibly find ways to detect Alzheimer's even earlier.
Boston, MassachusettsAges 55–80 - NCT06847321RecruitingPhase 2
Testing LHP588 for Alzheimer's linked to a mouth bacteria
This trial tests a new medication, LHP588, for people with Alzheimer's who also have a common mouth bacteria called P. gingivalis. The goal is to see if targeting this bacteria can help slow down memory loss.
Boston, MassachusettsAges 55–80 - NCT05462106RecruitingPhase 1/Phase 2
ACI-24.060 study for early Alzheimer’s in adults and Down syndrome
This Phase 1/2 study tests an Alzheimer’s treatment called ACI-24.060 to see if it affects the disease in people with early Alzheimer’s changes. It includes two groups: older adults with early symptoms and people with Down syndrome who also show Alzheimer’s-related changes on brain scans.
Boston, MassachusettsAges 35–85 - NCT05655195Recruiting
At-home light and sound therapy for mild Alzheimer’s
This study tests whether regular at-home “gamma” light and sound stimulation can help people with mild Alzheimer’s. Participants start with a month at home and are followed to see how they do during treatment.
Cambridge, MassachusettsAges 65–100 - NCT06489548RecruitingPhase 2
Foralumab for Early Alzheimer's Disease
This study tests an experimental drug called Foralumab, which aims to calm overactive immune cells in the brain linked to Alzheimer's. It may help slow memory loss in people with early-stage Alzheimer's.
Boston, MassachusettsAges 60–85 - NCT06860828Enrolling by invitation
Football players and brain health study: DIAGNOSE CTE
This study looks at brain changes in former college and professional football players, people with memory problems, and healthy controls. It aims to learn more about chronic traumatic encephalopathy (CTE) and Alzheimer's disease.
Boston, MassachusettsAges 50 years+ - NCT07659964Recruiting
Rhythmic music and walking study for Alzheimer's
This study tests whether listening to a steady beat (rhythmic music) while walking can improve movement and brain function in people with mild Alzheimer's disease. Healthy volunteers are also needed for comparison.
Boston, MassachusettsAges 50–90 - NCT05904132Recruiting
Brain stimulation therapy for early Alzheimer’s memory loss
This trial studies a “closed-loop” brain stimulation approach to improve symptoms in people with early Alzheimer’s-related memory problems. It may help by delivering stimulation based on your brain signals, if you meet the safety and diagnosis requirements.
Charlestown, MassachusettsAges 50–80 - NCT05776641Recruiting
Light and sound training to help prevent Alzheimer’s memory loss
This study tests whether regular “gamma” light and sound stimulation can delay or prevent Alzheimer’s disease-related memory decline in people who are currently not showing dementia but are at higher risk. It uses brain testing (MRI and PET) and memory/language tests over about 13 months.
Boston, MassachusettsAges 55–90 - NCT05984524Recruiting
Gamma music therapy for mild Alzheimer's disease
This study tests whether a specially designed music intervention can help people with mild Alzheimer's disease. You listen to music with a gamma frequency beat, which may improve brain function and memory.
Boston, MassachusettsAges 50–95 - NCT06297590RecruitingPhase 1
First human study of a new Alzheimer's drug
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
Charlestown, MassachusettsAges 50–85 - NCT06538311RecruitingEarly Phase 1
TMS treatment for early Alzheimer's disease
This study tests whether a non-invasive brain stimulation treatment called TMS (transcranial magnetic stimulation) can help people with early Alzheimer's disease or related memory problems. It's a safe, gentle way to stimulate brain cells using magnetic pulses.
Boston, MassachusettsAges 40–99 - NCT07169578RecruitingPhase 3
A study of trontinemab for early Alzheimer's disease
This trial tests a new drug called trontinemab for people with early Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
Boston, MassachusettsAges 50–90 - NCT07170150RecruitingPhase 3
A study of trontinemab for early Alzheimer's disease
This trial tests an investigational drug called trontinemab in people with early symptomatic Alzheimer's disease. It aims to see if it can slow down memory and thinking problems.
Boston, MassachusettsAges 50–90 - NCT07599670RecruitingPhase 1/Phase 2
Safety study of ABBV-1758 injection for Alzheimer's disease
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
Watertown, MassachusettsAges 50–90 - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Boston, MassachusettsAges 50–90 - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Newton, MassachusettsAges 60–85 - NCT06808984RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's disease
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Foxborough, MassachusettsAges 55–90 - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Worcester, MassachusettsAges 55–90 - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Methuen, MassachusettsAges 50–85 - NCT06956300Recruiting
TMS to help with thinking and memory in aging
This study uses a noninvasive brain stimulation technique called TMS to see if it can slow cognitive decline in older adults who are healthy or have very early signs of Alzheimer's disease. It aims to improve memory and thinking.
Boston, MassachusettsAges 40–99 - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Newton, MassachusettsAges 55–90 - NCT07011732RecruitingPhase 3
Testing a drug for Alzheimer's-related agitation
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Foxborough, MassachusettsAges 55–90 - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Belmont, MassachusettsAges 55–90
Alzheimer’s disease trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting alzheimer’s disease studies listed above.
- Massachusetts General Hospital · 6 studies
- Boston Center for Memory · 5 studies
- Adams Clinical · 4 studies
- Boston University · 3 studies
- Local Institution · 3 studies
- Brigham and Women's Hospital · 2 studies
- Elixia Health · 2 studies
- Headlands Research Eastern MA · 2 studies
What taking part in a alzheimer’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Alzheimer’s disease trials in other states
Common questions
- Are there alzheimer’s disease clinical trials in Massachusetts?
- Yes. We're currently tracking 50 recruiting alzheimer’s disease studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a alzheimer’s disease study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New alzheimer’s disease studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.